Synthesis and evaluation of novel radioiodinated nicotinamides for malignant melanoma

Nuclear Medicine and Biology

Volumn 35, Issue 7, 2008, Pages 769-781

  Liu, Xiang ^a   Pham, Tien Q ^a   Berghofer, Paula ^a   Chapman, Janette ^a   Greguric, Ivan ^a   Mitchell, Peter ^a   Mattner, Filomena ^a   Loc'h, Christian ^a   Katsifis, Andrew ^a  

^a AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION   (Australia)

Author keywords

A375 tumour; B16F0 tumour; Iodine 123; Iodonicotinamides; Melanoma; Small animal SPECT

Indexed keywords

HALOPERIDOL; IODINE 123; MELANIN; N [2 (DIETHYLAMINO)ETHYL] 5 IODONICOTINAMIDE I 123; NICOTINAMIDE; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG CLEARANCE; DRUG UPTAKE; FEMALE; LIPOPHILICITY; MELANOMA; METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; RADIOACTIVITY; RADIOIODINATION; RECEPTOR BINDING; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TISSUE DISTRIBUTION; URINARY EXCRETION;

ANIMALS; FEMALE; IODINE RADIOISOTOPES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NIACINAMIDE; RADIOPHARMACEUTICALS; SOLUBILITY; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 53249144055     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2008.05.011     Document Type: Article

References (34)

1. Baade P., and Coory M. Trends in melanoma mortality in Australia: 1950-2002 and their implications for melanoma control. Aust N Z J Public Health 29 (2005) 383-386
2. 123,131I]iodobenzamides by animal and cell-culture studies. J Lab Comp Radiopharm 37 (1995) 260-262
3. John C.S., Bowen W.D., Saga T., Kinuya S., Vilner B.J., Baumgold J., et al. A malignant melanoma imaging agent: synthesis, characterization, in vitro binding and biodistribution of iodine-125-(2-piperidinylaminoethyl)4-iodobenzamide. J Nucl Med 34 (1993) 2169-2175
4. Labarre P., Papon J., Moreau M.F., Moins N., Veyre A., and Madelmont J.C. Evaluation in mice of some iodinated melanoma imaging agents using cryosectioning and multi-wire proportional counting. Eur J Nucl Med 26 (1999) 494-498
5. Pham T.Q., Greguric I., Liu X., Berghofer P., Ballantyne P., Chapman J., et al. Synthesis and evaluation of novel radioiodinated benzamides for malignant melanoma. J Med Chem 50 (2007) 3561-3572
6. Eisenhut M., Hull W.E., Mohammed A., Mier W., Lay D., Just W., et al. Radioiodinated N-(2-diethylaminoethyl)benzamide derivatives with high melanoma uptake: structure-affinity relationships, metabolic fate, and intracellular localization. J. Med. Chem 43 (2000) 3913-3922
7. Brandau W., Niehoff T., Pulawski P., Jonas M., Dutschka K., Sciuk J., et al. Structure distribution relationship of iodine-123-iodobenzamides as tracers for the detection of melanotic melanoma. J Nucl Med 37 (1996) 1865-1871
8. Michelot J.M., Moreau M.F., Veyre A.J., Bonafous J.F., Bacin F.J., Madelmont J.C., et al. Phase II scintigraphic clinical trial of malignant melanoma and metastases with iodine-123-N-(2-diethylaminoethyl 4-iodobenzamide). J Nucl Med 34 (1993) 1260-1266
9. 123I-N-(2-Diethylaminoethyl)-2-iodobenzamide: a potential imaging agent for cutaneous melanoma staging. Eur J Nucl Med Mol Imaging 29 (2002) 1478-1484
10. 123I-N-(2-diethylaminoethyl)-2-iodobenzamide in the diagnostic of primary and metastatic ocular melanoma. J Fr Ophthalmol 27 (2004) 34-39
11. Larisch R., Schulte K.W., Vosberg H., Ruzicka T., and Muller-Gartner H.W. Differential accumulation of iodine-123-iodobenzamide in melanotic and amelanotic melanoma metastases in vivo. J Nucl Med 39 (1998) 996-1001
12. Salopek T.G., Scott J.R., Joshua A.V., Smylie M., Logus J.W., Morin C.A., et al. Radioiodinated N-[3-(4-morpholino)propyl]-N-methyl-2-hydroxy-5-iodo-3-methyl benzylamine (ERC9): a new potential melanoma imaging agent. Eur J Nucl Med 28 (2001) 408-417
13. Nicholl C., Mohammed A., Hull W.E., Bubeck B., and Eisenhut M. Pharmacokinetics of iodine-123-IMBA for melanoma imaging. J Nucl Med 38 (1997) 127-133
14. Brown J.M., Lemmon M.J., Horsman M.R., and Lee W.W. Structure-activity relationships for tumour radiosensitization by analogues of nicotinamide and benzamide. Int J Radiat Biol 59 (1991) 739-748
15. Pero R.W., Axelsson B., Siemann D., Chaplin D., and Dougherty G. Newly discovered anti-inflammatory properties of the benzamides and nicotinamides. Mol Cell Biochem 193 (1999) 119-125
16. Girgis A.S., Hosni H.M., and Barsoum F.F. Novel synthesis of nicotinamide derivatives of cytotoxic properties. Bioorg Med Chem 14 (2006) 4466-4476
17. Moins N., Papon J., Seguin H., Gardette D., Moreau M.F., Labarre P., et al. Synthesis, characterization and comparative biodistribution study of a new series of p-iodine-125 benzamides as potential melanoma imaging agents. Nucl Med Biol 28 7 (2001) 799-808
18. Waterhouse R.N. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. Mol Imaging Biol 5 (2003) 376-389
19. Chaki S., Tanaka M., Muramatsu M., and Otomo S. NE-100, a novel potent sigma ligand, preferentially binds to sigma 1 binding sites in guinea pig brain. Eur J Pharmacol 251 (1994) R1-R2
20. Brent P.J., and Pang G.T. Sigma binding site ligands inhibit cell proliferation in mammary and colon carcinoma cell lines and melanoma cells in culture. Eur J Pharmacol 278 (1995) 151-160
21. Salazar-Bookaman M.M., Wainer I., and Patil P.N. Relevance of drug-melanin interactions to ocular pharmacology and toxicology. J Ocul Pharmacol 10 (1994) 217-239
22. Labarre P., Papon J., Moreau M.F., Moins N., Bayle M., Veyre A., et al. Melanin affinity of N-(2-diethylaminoethyl)-4-iodobenzamide, an effective melanoma imaging agent. Melanoma Res 12 (2002) 115-121
23. Dittmann H., Coenen H.H., Zolzer F., Dutschka K., Brandau W., and Streffer C. In vitro studies on the cellular uptake of melanoma imaging aminoalkyl-iodobenzamide derivatives (ABA). Nucl Med Biol 26 (1999) 51-56
24. Vilner B.J., John C.S., and Bowen W.D. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res 55 (1995) 408-413
25. Bem W.T., Thomas G.E., Mamone J.Y., Homan S.M., Levy B.K., Johnson F.E., et al. Overexpression of sigma receptors in nonneural human tumors. Cancer Res. 51 (1991) 6558-6562
26. 2), an imaging agent for melanoma staging: relation to pigmentation. Nucl Med Biol 32 (2005) 451-458
27. John C.S., Vilner B.J., Geyer B.C., Moody T., and Bowen W.D. Targeting sigma receptor-binding benzamides as in vivo diagnostic and therapeutic agents for human prostate tumors. Cancer Res 59 (1999) 4578-4583
28. John C.S., Bowen W.D., Varma V.M., McAfee J.G., and Moody T.W. Sigma receptors are expressed in human non-small cell lung carcinoma. Life Sci 56 (1995) 2385-2392
29. Chehade F., Michelot J., Hindie E., Papon J., Delabriolle-Vaylet C., Zhang L., et al. Localization of N-(2-diethylaminoethyl)4-iodobenzamide in the pigmented mouse eye: a microanalytical study. Cell Mol Biol 42 (1996) 343-350
30. Mohammed A., Nicholl C., Titsch U., and Eisenhut M. Radioiodinated N-(alkylaminoalkyl)-substituted 4-methoxy-, 4-hydroxy-, and 4-aminobenzamides biological investigations for the improvement of melanoma-imaging agents. Nucl Med Biol 24 (1997) 373-380
31. 123I-MEL037, for malignant melanoma. J Nucl Med 48 (2007) 1348-1356
32. Moreau M.F., Papon J., Labarre P., Moins N., Borel M., Bayle M., et al. Synthesis, in vitro binding and biodistribution in B16 melanoma-bearing mice of new iodine-125 spermidine benzamide derivatives. Nucl Med Biol 32 (2005) 377-384
33. Wolf M., Bauder-Wust U., Haberkorn U., Mier W., and Eisenhut M. Alkylating benzamides with melanoma cytotoxicity: role of melanin, tyrosinase, intracellular pH and DNA interaction. Melanoma Res 15 (2005) 383-391
34. Wolf M., Bauder-Wust U., Mohammed A., Schonsiegel F., Mier W., Haberkorn U., et al. Alkylating benzamides with melanoma cytotoxicity. Melanoma Res 14 (2004) 353-360